US 12,240,830 B2
Fused ring heteroaryl compounds and use thereof
Jinwoo Lee, Seongnam-si (KR); Byungnam Kang, Seongnam-si (KR); Youngdo Shin, Seongnam-si (KR); Namhee Kim, Seongnam-si (KR); Jungwoo Lee, Seongnam-si (KR); Hongjun Kang, Seongnam-si (KR); Sunjoo Kim, Seongnam-si (KR); Inho Yang, Seongnam-si (KR); Cheolhwan Yoon, Seongnam-si (KR); Cheolkyu Han, Seongnam-si (KR); and Jeongbeob Seo, Seongnam-si (KR)
Assigned to BiSiChem Co., Ltd., Seongnam-si (KR)
Filed by BiSiChem Co., Ltd., Seongnam-si (KR)
Filed on Aug. 13, 2022, as Appl. No. 17/887,424.
Claims priority of provisional application 63/232,808, filed on Aug. 13, 2021.
Prior Publication US 2023/0089180 A1, Mar. 23, 2023
Int. Cl. C07D 401/14 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 31/4439 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01)] 3 Claims
 
1. A compound of formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, or tautomer thereof;

OG Complex Work Unit Chemistry
wherein;
R1 is independently selected from the group consisting of H, C1-C6 alkyl, CD3, CHF2, CF3, —(C1-C6) hydroxyalkyl, and —SO2alkyl;
R2 is independently selected from the group consisting of H, Me, CF3, NO2, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6haloalkyl, C3-C7cycloalkyl, alkylcarboxy, cyano, and alkoxy;
X1, X2 and X3 are each independently CH or N;
each R3 is independently selected from the group consisting of hydrogen, halogen, CF3, amino, substituted amino, C1-C6alkyl, substituted C1-C6alkyl, C1-C6haloalkyl, C3-C7cycloalkyl, alkylcarboxy, cyano, nitro, and alkoxy;
each R4 is independently selected from the group consisting of hydrogen, halogen, CF3, amino, substituted amino, C1-C6alkyl, substituted C1-C6alkyl, C1-C6haloalkyl, cyano, nitro, alkoxy, and aryloxy;
m is 1, 2, 3 or 4; and
n is 1, 2, 3, 4 or 5.